Efficacy

Introduction to Tagrisso (Osimertinib) in Lung Cancer Treatment

Tagrisso (osimertinib) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to treat patients with non-small cell lung cancer (NSCLC) whose tumors have specific EGFR mutations. It is particularly effective against the T790M mutation, which is a common resistance mechanism to earlier generations of EGFR TKIs. Clinical trials have demonstrated that osimertinib is effective in both the first-line treatment setting and in patients who have developed resistance to first-generation EGFR TKIs.

Efficacy of Tagrisso in First-Line Treatment of NSCLC

In the first-line treatment setting, the FLAURA study showcased the efficacy of osimertinib in patients with advanced NSCLC harboring EGFR mutations. The study found that osimertinib significantly improved progression-free survival (PFS) compared to standard EGFR TKIs (gefitinib or erlotinib). The median PFS for patients treated with osimertinib was 18.9 months, compared to 10.2 months for those on standard therapy. Additionally, the overall survival (OS) benefit was also notable, with a median OS of 38.6 months for osimertinib versus 31.8 months for the comparator group.

Tagrisso for T790M-Positive NSCLC After Resistance to First-Line EGFR TKIs

For patients whose disease has progressed on or after first-line EGFR TKI therapy and who have developed the T790M resistance mutation, osimertinib has shown substantial efficacy. The AURA3 trial demonstrated that osimertinib improved PFS compared to platinum-based chemotherapy in this patient population. The median PFS was 10.1 months for osimertinib compared to 4.4 months for chemotherapy. This highlights osimertinib's role as a preferred treatment option for T790M-positive NSCLC following resistance to initial EGFR TKI therapy.

Efficacy of Augtyro (Repotrectinib) in Lung Cancer Treatment

Augtyro (repotrectinib) is a newer, investigational TKI with activity against ROS1 and TRK fusions as well as ALK mutations. While its use in lung cancer is currently being evaluated in clinical trials, preliminary data suggest that repotrectinib has potent antitumor activity in patients with ROS1-positive NSCLC. Early-phase trials have shown promising response rates in both treatment-naïve and pretreated patients with ROS1-fusion-positive NSCLC. However, as repotrectinib is still under investigation, further studies are required to fully establish its efficacy and safety profile in the lung cancer treatment landscape.